Recent results on aromatase inhibitors for breast cancer prevention have shown that AIs have fewer serious adverse events (i.e., endometrial cancer and venous thromboembolism) than tamoxifen or raloxifene, which may offset their higher upfront drug costs. This evidence concerns the gene CYP19A1 and venous thromboembolism.